Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. News
  7. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  04:24 2022-10-06 am EDT
12.74 EUR   +1.11%
09/06Pleco Therapeutics B.V. announced that it has received €4.6 million in funding from Hyloris Pharmaceuticals SA, Oost NL BV
CI
09/06Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris Pharmaceuticals SA
CI
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hyloris Reports Positive Phase 1 Data for HY-004, A Proprietary Tranexamic Acid Oral Mouth Rinse for Bleeding Related to Dental Procedures

07/20/2022 | 01:00am EDT

Hyloris Pharmaceuticals SA announced positive results from a Phase 1 study of HY-004, an antifibrinolytic agent, tranexamic acid, as an oral mouth rinse proprietary formulation (Tranexamic Acid Oral Solution, 5%) in healthy patients following tooth extraction. HY-004 is being developed for use in patients on anti-coagulant therapies that are undergoing dental procedures with the potential for complications/bleeding. The study results showed that HY-004 was found to be well-tolerated under varied conditions with no serious adverse events following tooth extraction, while effectively controlling procedural bleeding without delaying clot formation.

Hyloris also plans to investigate its use for broader related indications in patients undergoing oral surgical procedures with or without bleeding disorders that would benefit from a locally-acting antifibrinolytic agent.


© S&P Capital IQ 2022
All news about HYLORIS PHARMACEUTICALS SA
09/06Pleco Therapeutics B.V. announced that it has received €4.6 million in funding fro..
CI
09/06Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris..
CI
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
09/01HYLORIS PHARMACEUTICALS SA : Half-year report
CO
09/01HYLORIS PHARMACEUTICALS SA : 1st-half-year results
CO
08/31Hyloris Pharmaceuticals : 2022 Half-year KPMG Report
PU
08/31Hyloris Pharmaceuticals : 2022 Half-year Report
PU
07/20Hyloris' Oral Mouth Rinse Shows Controlled Bleeding After Tooth Extraction in Early-sta..
MT
07/20Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mo..
GL
More news
Financials
Sales 2022 5,00 M 4,93 M 4,93 M
Net income 2022 -11,0 M -10,8 M -10,8 M
Net cash 2022 27,0 M 26,6 M 26,6 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 338 M 333 M 333 M
EV / Sales 2022 62,1x
EV / Sales 2023 22,1x
Nbr of Employees 21
Free-Float 52,2%
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 12,60 €
Average target price 20,25 €
Spread / Average Target 60,7%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer & Executive Director
Jean-Luc Vandebroek Chief Financial Officer
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA-27.17%333
JOHNSON & JOHNSON-3.48%434 104
ELI LILLY AND COMPANY19.43%315 249
ROCHE HOLDING AG-13.48%273 724
ABBVIE INC.5.86%253 421
PFIZER, INC.-25.28%247 617